NASDAQ:CTKB - Nasdaq - US23285D1090 - Common Stock - Currency: USD
5.12
-0.08 (-1.54%)
The current stock price of CTKB is 5.12 USD. In the past month the price decreased by -10.02%. In the past year, price decreased by -41.28%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
DHR | DANAHER CORP | 28.07 | 151.18B | ||
A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
WAT | WATERS CORP | 31.58 | 22.26B | ||
ICLR | ICON PLC | 14.39 | 16.63B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
RVTY | REVVITY INC | 23.23 | 13.85B | ||
AVTR | AVANTOR INC | 17.3 | 11.78B | ||
TEM | TEMPUS AI INC | N/A | 10.72B |
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 645 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
CYTEK BIOSCIENCES INC
47215 Lakeview Boulevard
Fremont CALIFORNIA US
Employees: 645
Company Website: https://cytekbio.com
Investor Relations: https://investors.cytekbio.com/
Phone: 18779229835
The current stock price of CTKB is 5.12 USD. The price decreased by -1.54% in the last trading session.
The exchange symbol of CYTEK BIOSCIENCES INC is CTKB and it is listed on the Nasdaq exchange.
CTKB stock is listed on the Nasdaq exchange.
12 analysts have analysed CTKB and the average price target is 8.16 USD. This implies a price increase of 59.38% is expected in the next year compared to the current price of 5.12. Check the CYTEK BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CYTEK BIOSCIENCES INC (CTKB) has a market capitalization of 659.51M USD. This makes CTKB a Small Cap stock.
CYTEK BIOSCIENCES INC (CTKB) currently has 645 employees.
CYTEK BIOSCIENCES INC (CTKB) has a support level at 4.81 and a resistance level at 5.15. Check the full technical report for a detailed analysis of CTKB support and resistance levels.
The Revenue of CYTEK BIOSCIENCES INC (CTKB) is expected to grow by 6.31% in the next year. Check the estimates tab for more information on the CTKB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CTKB does not pay a dividend.
CYTEK BIOSCIENCES INC (CTKB) will report earnings on 2025-02-27, after the market close.
CYTEK BIOSCIENCES INC (CTKB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
The outstanding short interest for CYTEK BIOSCIENCES INC (CTKB) is 2.71% of its float. Check the ownership tab for more information on the CTKB short interest.
ChartMill assigns a fundamental rating of 4 / 10 to CTKB. CTKB has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months CTKB reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS decreased by -215.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -3.63% | ||
ROE | -4.51% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 77% to CTKB. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -241.55% and a revenue growth 6.31% for CTKB